Conférenciers inspirants

Antonis Antoniou, PhD
Professor of Cancer Risk Prediction, University of Cambridge, Cambridge, United Kingdom

Professor Antoniou currently leads a research team within the Department of Public Health and Primary Care and is the Academic Course Director for the MPhil in Epidemiology.

His main research is the development and application of statistical modelling techniques for addressing clinical questions, and the development of risk prediction tools which are used in clinical practice. He is the principal developer of the risk prediction algorithm "BOADICEA" for breast and ovarian cancer. He has developed novel statistical techniques for modelling disease susceptibility and has applied these methods for the accurate risk characterisation of rare mutations in BRCA1, BRCA2, PALB2 and other cancer susceptibility genes. He established the CIMBA data coordinating centre in 2006 and led the analytical efforts of the consortium since its inception.

Invited Speaker, Symposium

Mark Basik, MD
Attending Surgical Oncologist, Department of Surgery & Oncology, Jewish General Hospital, Montréal, QC, Canada

Dr. Basik was born in Montreal, graduated in medicine from McGill University, completed a general Surgery Residency at the Université de Montreal, followed by a fellowship in Surgical Oncology at Roswell Park Cancer Institute. He was a visiting investigator at the National Institutes of Health in Bethesda. He returned to Montreal in 2003, where he is now practicing breast cancer surgery at the Jewish General Hospital in Montréal, QC, and he is the Herbert Black professor of Surgical Oncology at McGill University. He heads the Cancer Genomics and Translational Research Laboratory at the Lady Davis Institute for Medical Research. His research interests include understanding the causes of resistance to therapy in breast cancer as well as developing new diagnostic blood tests for breast cancer.

Invited Speaker, Public Conference

Jonathan Sanford Berg, MD
University of North Carolina School of Medicine, Chapel Hill, NC, United States

Dr. Berg is a graduate of the MD/PhD program at the University of North Carolina at Chapel Hill, and he completed residency training in Clinical Genetics at Baylor College of Medicine. He is currently Director of the UNC Cancer and Adult Genetics Clinic, which provides consultation and genetic counseling for patients at risk for hereditary conditions. He also directs the Program for Precision Medicine in Health Care, which among a number of initiatives is collaborating with the UNC Health system to implement a framework for storing structured genetic data that can be used to drive computational analysis and decision support. The clinical group is particularly interested in facilitating genetic testing in cancer patients and leveraging the electronic health record for population management of patients with hereditary cancer predisposition. Dr. Berg’s research focuses on clinical and translational approaches to investigate the implementation of genomic medicine for diagnosis and screening of monogenic disorders in all age groups. He is also a PI within the Clinical Genome Resource (“ClinGen”) project, which aims to provide a freely available and expertly curated resource for clinically relevant genes and variants. The UNC ClinGen team helped to initiate the Hereditary Cancer Clinical Domain Working Group and team members led or were heavily involved in several expert panels that addressed gene-disease validity in hereditary cancer predisposition syndromes. Dr. Berg’s research group has also contributed to ClinGen’s approach to the use of functional assays for variant classification.

Invited Speaker, Symposium

Jennifer Blake, MD
Society of Obstetricians and Gynaecologists of Canada, Ottawa, ON, Canada

Dr. Blake is Chief Executive Officer of the Society of Obstetricians and Gynaecologists of Canada (SOGC), which is a leading authority on women’s sexual and reproductive health. She is an experienced physician and respected leader who has facilitated major organizational change in both hospital and academic sectors. During her 30-year medical career, she has held several clinical, academic and leadership roles, including Chief of obstetrics and gynaecology and Head of women’s health at the Sunnybrook Health Sciences Centre, Chief of pediatric gynaecology at the Hospital for Sick Children in Toronto and Undergraduate Dean of McMaster University’s medical school. She has also served as professor and associate chair at the University of Toronto, as well as head of pediatric gynaecology for the school. She is Adjunct Professor at the University of Ottawa.

Dr. Blake brings a national perspective to her work from her experience with the SOGC, the Medical Council of Canada, the Royal College of Physicians and Surgeons of Canada, the Association of Academic Professionals in Obstetrics and Gynaecology of Canada, and the Canadian Foundation for Women’s Health. In 2013, she was awarded a Fellowship Honoris Causa by the Royal College of Obstetricians and Gynaecologists (UK) for her work as a passionate advocate and trusted spokeswoman on issues relating to women’s health. She is also a member of International Editorial Board of The Global Library of Women’s Medicine (GLOWM). In 2011, Dr. Blake was identified as one of the top 25 women of influence in Canada.

Invited Speaker, Public Conference

Kyra Bokkers, MD
PhD Student, University Medical Center Utrecht, Utrecht, The Netherlands

Dr. Bokkers studied Medicine at the University of Groningen, The Netherlands. From September 2017 onwards she has been employed at the Department of Genetics of the University Medical Center Utrecht and involved in the development and implementation of mainstreaming genetic testing projects in cancer care. She started her PhD in 2019.

Proffered Paper, Symposium

Nathalie Bolduc, MSc
Director, Business Development at Genolife and Consultant, Genetic and Prevention Program at Quebec Breast Cancer Foundation, Montreal, QC, Canada

Nathalie Bolduc is currently the Director of the Breast Cancer Genetics and Prevention Program at the Quebec Breast Cancer Foundation. She is an experienced genetic counsellor with a unique combination of clinical expertise in the public and private healthcare sectors as well as in research and industry. She worked several years with French Canadian BRCA families and later joined the McGill University Health Centre and worked in several clinical settings including prenatal diagnosis, reproductive technologies, pediatric and adult genetics. She directed the provincial predictive testing program for Huntington disease and collaborated with a First Nations community to develop educational videos for this condition. She was the president of the Quebec Association of Genetic Counsellors from 2007 to 2013. She currently is the Past President II of the Canadian Association of Genetic Counsellors.

Invited Speaker, Symposium

Yvonne Bombard, PhD, BSc
Scientist, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada

Dr. Bombard is a genomics health services researcher and Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Associate Professor at the University of Toronto in the Institute of Health Policy Management and Evaluation. Her research focuses on evaluating the adoption of new genomic technologies in clinical practice. She develops patient-facing digital tools for precision medicine and evaluates their comparative effectiveness to inform clinical translation. She is active in numerous international policy advisory committees; her research informs policy development in this area. In 2014, Dr. Bombard was the inaugural recipient of the Maurice McGregor Award for Demonstrated Excellence and Leadership Potential from the Canadian Agency for Drugs and Technologies in Health (CADTH) and also received a ‘Rising Star’ award from CIHR’s Institute of Health Services and Policy Research in 2011. She was awarded a CIHR Foundation grant as an Early Career Investigator, and a CIHR New Investigator Award. She holds Fellowships from: Yale University (in Health Policy), Memorial Sloan-Kettering Cancer Center (in Cancer Genomics) and the University of Toronto (in Health Services Research).

Invited Speaker, Symposium

Lawrence Brody, PhD
Director, Division of Genomics and Society. National Human Genome Research Institute, Bethesda, MD, United States

Dr. Brody is a Senior Investigator in the National Human Genome Research Institute (NHGRI) at the NIH. He studied biology with an emphasis on genetics as an undergraduate at Penn State University. He received his PhD in Human Genetics from Johns Hopkins University in 1991. He then held postdoctoral appointments at Johns Hopkins School of Medicine and the University of Michigan. He joined the faculty of NHGRI in 1993 and from 2010 to 2014 he served as the Chief of NHGRI’s Genome Technology Branch. In 2013 he was named Director of the Division or Genomics and Society one of NHGRI three extramural divisions. He also serves as the Chief Scientific Officer for NIH’s Center for Inherited Disease Research, a high throughput genotyping and sequencing center that serves 10 of NIH’s 27 institutes.

Dr. Brody’s lab investigates the genetics of cancer, metabolism, birth defects and the use application of genetics to clinical care. As head of the Genetics and Environment Interaction Section, he is interested in using multidisciplinary approaches to understand how inherited variations lead to perturbations in normal metabolic pathways and cause disorders such as cancer and birth defects. His laboratory investigates mutations in two known breast cancer-linked genes, breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2), and their roles in inherited breast and ovarian cancer susceptibility. His group discovered an unusually high frequency of specific BRCA1 mutations in the Jewish population. The Brody lab is also studied the function of BRCA1 using combined cell biological and biochemical approaches.

Invited Speaker, Symposium

Adam Buchanan, MS, MPH
Associate Professor, Geisinger Health, Danville, PA, United States

Adam Buchanan is a certified genetic counselor and associate professor in the Geisinger Genomic Medicine Institute and President of the American Board of Genetic Counseling. He received his master’s in public health, with a focus in health behavior and health education, at the University of North Carolina in Chapel Hill, and master’s in science in genetic counseling at the University of North Carolina in Greensboro. His research focuses on the clinical utility of genomic screening in unselected populations, assessing the effectiveness of alternate service delivery models for improving access to genomic services, and clinical outcomes of genetic counseling.

Invited Speaker, Symposium

Ian Campbell, PhD
Group Leader, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Professor Campbell is co-Head of the Women’s Cancer Program at the Peter MacCallum Cancer Centre, Melbourne, Australia and lead investigator of Lifepool study ( A major component of his research is the discovery of new familial breast and ovarian cancer predisposition genes through large scale sequencing approaches. He has also made significant contributions to the understanding of the etiology of ovarian cancer.

Proffered Paper, Symposium

Elena Castro, MD, PhD
CNIO-IBIMA Genitourinary Cancer Research Unit, Biomedical Research Institute of Malaga (IBIMA), Málaga, Spain

Dr. Castro is a medical oncologist and physician scientist specialized in the treatment of patients with prostate cancer. After completing her training in Medical Oncology in Spain, she spent four years as clinical research fellow at the Royal Marsden Hospital training in cancer genetics. Her research has focused on understanding the implications of inherited genetic variants in the outcomes of prostate cancer and the molecular characterization of those tumours. Dr. Castro’s clinical practice manages men with prostate cancer the majority of whom are treated in the setting of clinical trials.

Invited Speaker, Symposium

Stephen Chanock, MD
Director, National Cancer Institute, Rockville, MD, United States

Dr. Chanock is the Director of the NCI Division of Cancer Epidemiology and Genetics (DCEG). A leading expert in the discovery and characterization of cancer susceptibility regions in the human genome, he has received numerous awards for his scientific contributions to our understanding of common inherited genetic variants associated with cancer risk and outcomes. He received his M.D. from Harvard Medical School and completed clinical training in pediatrics, pediatric infectious diseases, and pediatric hematology/oncology and research training in molecular genetics at Boston Children’s Hospital and the Dana-Farber Cancer Institute, Boston. From 2001-2007, he was a tenured investigator in the Genomic Variation Section of the Pediatric Oncology Branch in the NCI Center for Cancer Research. He also served as co-chair of NCI's Genetics, Genomics and Proteomics Faculty for five years. In 2001, he was appointed as Chief of the Cancer Genomics Research Laboratory (formerly Core Genotyping Facility), and in 2007 as Chief of the Laboratory of Translational Genomics, both within DCEG. From 2012 to 2013, he served as Acting Co-Director of the NCI Center for Cancer Genomics and was appointed Director of DCEG in August 2013. Since 1995, he has served as the Medical Director for Camp Fantastic, a week-long recreational camp for pediatric cancer patients, a joint venture of the NCI and Special Love, Inc..

Invited Speaker, Symposium

Blaise Clarke, MD
University of Toronto, Toronto General Hospital, Toronto, ON, Canada

Dr. Clarke is a gynecological pathologist with a strong interest in molecular characterisation. He uses his expertise with molecular pathology techniques to study gynecological tumours, common and rare.

Invited Speaker, Symposium

Robert Cook-Deegan, MD
Professor, Arizona State University, Washington, DC, United States

Professor Cook-Deegan is a professor in the School for the Future of Innovation in Society, and with the Consortium for Science, Policy & Outcomes at Arizona State University. He founded and directed Duke’s Center for Genome Ethics, Law & Policy 2002-2012, and taught in Duke’s in-Washington program through June 2016. Before Duke he worked at the National Academies of Science, Engineering and Medicine 1991-2002; National Center for Human Genome Research (NIH) 1989-1990; and congressional Office of Technology Assessment 1982-1988. He obtained his MD from the University of Colorado in 1979; and a BA in chemistry (magna cum laude) from Harvard in 1975. He is the author of The Gene Wars: Science, Politics, and the Human Genome and over 300 other publications.

Invited Speaker, Symposium

Fergus J. Couch, PhD
Professor of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States

Dr. Couch is a Professor of Laboratory Medicine and Pathology and the Chair of the Division of Experimental Pathology and Laboratory Medicine at Mayo Clinic. He is the recipient of the Zbigniew and Anna M. Scheller Professorship in Medical Research. He studies the genetics of breast and pancreatic cancer and has a particular interest in understanding inherited forms of these cancers. He is a co-founder of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium that is working to establish the risks of cancers associated with inherited variants in all breast cancer predisposition genes.

Invited Speaker, Symposium

Christopher Crum, MD
Senior Pathologist, Brigham and Women's Hospital, Boston, MA, USA

Dr Crum is a Professor of Pathology at Harvard Medical School and Senior Pathologist at Brigham and Women’s Hospital. In 2005 he developed the SEE-FIM dissection protocol, revealing the fimbria as a site of origin for many serous cancers in women with germ-line BRCA mutations. His extended this model to explain serous carcinogenesis in all women, highlighting the tube as both a site of early cancers and a potential launching point for precursor cells that could lead to “primary peritoneal” carcinomas. Dr. Crum recently received the 2019 Innovation Award from the Society of Gynecologic Oncology for his contributions to research in gynecologic cancer.

Invited Speaker, Symposium

Adeline Cuggia, MSc, CCGC
Genetic Counsellor / Research Coordinator, Research Institute of the McGill University Health Centre, Montréal, QC, Canada

Adeline Cuggia graduated from Genetic Counselling at Université de Montréal in 2014. She has been working on pancreatic cancer research at the Research Institute of the MUHC since 2015, where she is using her genetics expertise to bring patients exciting new research initiatives from the laboratory to the clinic.

Speaker in the Public Conference.

Peter Davison, MD, SM Epi, FRCSC
Assistant Professor, Division Plastic Surgery, McGill University Health Centre (MUHC), Montréal, QC, Canada

Dr Davison, an assistant professor of surgery at McGill University, Montréal, Québec, graduated from the University of Calgary medical school in 2009. He completed his residency in Plastic Surgery at Dalhousie University in 2014, followed by a fellowship in Microsurgery at the University of Manitoba in 2015 and in Breast and Aesthetic Surgery at the University of British Columbia in 2015. His clinical interests are Breast Surgery, Oncology Reconstruction and Aesthetics. His research Interestsare breast reconstruction and patient-reported outcomes.

Speaker in the Public Conference.

Douglas Easton, PhD
Director, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK

Professor Easton is a leading genetic epidemiologist with a specific interest in the genetics of hormone related cancers. His studies have been instrumental in the characterisation of many cancer susceptibility genes, including BRCA1, BRCA2, CHEK2 and ATM, and the identification of more than 200 common cancer susceptibility variants.

In 2007 he led the first genome-wide association study in breast cancer. Professor Easton leads the Breast Cancer Association Consortium, a collaboration involving more than 100 research groups and 300,000 subjects. He leads the EMBRACE cohort study of BRCA1/2 mutation carriers, and initiated the BOADICEA risk prediction model, used in genetic counselling worldwide.

Proffered Paper, Symposium

Harley Eisman, MD
Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada
Chair of the International Symposium on Hereditary Breast and Ovarian Cancer

Dr. Eisman is Director of Pediatric Emergency Medicine at The Montreal Children's Hospital and Co-Founder of the Hereditary Breast and Ovarian Cancer Foundation. He is a graduate of the McGill University Medical School, did his Pediatric Residency Training at The Montreal Children’s Hospital and completed a fellowship in Pediatric Emergency Medicine after being Chief Pediatric Resident at The Montreal Children’s Hospital.

Co-Chair, Symposium

Caitlin Fierheller, BSc
PhD candidate, Dept. of Human Genetics, McGill University, Montréal, QC, Canada

Caitlin Fierheller is a doctoral candidate in Human Genetics, McGill University under the supervision of Dr. Patricia Tonin (Full Professor, Medicine & Human Genetics, McGill) Cancer Research Program, Centre for Translational Biology, The Research Institute of the McGill University Health Centre. Her research focuses on the molecular genetics of germline potentially pathogenic variants in DNA repair pathway genes in familial ovarian cancer.

Proffered Paper, Symposium

William D. Foulkes, MBBS, PhD, FRCP, FRSC
Departments of Human Genetics, Medicine and Oncology, McGill University, Montréal, QC, Canada

Dr. Foulkes is a physician trained in medicine in the United Kingdom and in Canada. He obtained his Ph.D. from the Imperial Cancer Research Fund, London, in 1994, before moving to Montréal later that year. He obtained his Québec specialist certification in Medical Genetics in 2000. His main research interests include investigation of the hereditary factors in breast and colorectal cancer, as well as in rare tumors.

He is a James McGill Professor in the Departments of Medicine, Human Genetics and Oncology and the Director of the Cancer Genetics program at McGill University in Montréal, QC, Canada. Among others, he is funded by the Canadian Institutes of Health Research (CIHR), the Quebec Breast Cancer Foundation, the C17 Research Fund and the US Department of Defense.

Co-Chair, Symposium

Simon Gayther, PhD
Barth Family Chair in Cancer Genetics in honor of Beth Y. Karlan, MD, Director, Molecular Epidemiology, Co-Director, Center for Bioinformatics and Functional Genomics, Cedars Sinai Medical Center, Los Angeles, CA, United States

Dr. Gayther directs the Center for Bioinformatics and Functional Genomics at Cedars Sinai Medical Center, Los Angeles. He has studied BRCA1 and BRCA2 in breast and ovarian cancer for more than 25 years, first characterizing the prevalence and penetrance of BRCA1/2 mutations in breast/ovarian cancer families, then showing that for each gene mutation location affects breast and ovarian cancer risks. He has established population based frequencies of BRCA1, BRCA2 and associated genes (BRIP1, RAD51C, RAD51D) in ovarian cancer using whole exome and targeted sequencing, and modeled of the effects of mutations in these genes in early stage breast/ovarian cancer development

Proffered Paper, Symposium

Lucy Gilbert, MD, MSc, FRCOG
Professor, Departments of Oncology and Obstetrics and Gynecology, McGill University Health Centre (MUHC), Montréal, QC, Canada

Dr. Lucy Gilbert is a Professor in the Department of Obstetrics & Gynecology and the Department of Oncology at McGill University. She heads the Tertiary/Quaternary Care Gynecologic Cancer Service of the McGill University Health Centre (MUHC) as well as its Women’s Health Research Unit. Her research focuses on novel therapeutic options for the treatment of ovarian and uterine cancers as well as technologies for their early detection. She has set up a network of satellite clinics as part of the DOvEE (Diagnosing Ovarian and Endometrial Cancers Early) project, which provide open access investigations for women with symptoms associated with gynecologic cancers. She and her team have recently developed an innovative genomic uterine pap-test called DOvEEgene to detect these cancers before they cause symptoms and are still confined to the gynecologic organ and therefore curable. DOvEEgene will be offered to women aged 45-70 years in the context of a Clinical trial starting after World Ovarian Cancer day 2021.

Speaker in the Public Conference.

Laura Hayes
Clinical Care Coordinator, Genetic Oncology, Department of Human Genetics, McGill University, Montréal, QC, Canada

Laura Hayes graduated in Nursing in 1990. As the Clinical Care Coordinator for the BRCA1 and BRCA2 mutation carriers, Laura gets to put her nursing skills into practice by managing the screening and clinical aspects of patient care, as well as providing support and advocacy.

Chair, Public Conference

Zhengcheng He, BSc
PhD student, University of British Columbia, Vancouver, BC, Canada

Zhengcheng He is a doctoral student working under the supervision of Dr. Maxwell at UBC. His research interests are in BRCA1, mitosis, and mammary epithelial cell. His recent work is trying to investigate how BRCA1 impacts cell division axis to regulate mammary cell phenotype.

Proffered Paper Symposium

Nicoline Hoogerbrugge, MD, PhD
Professor in Hereditary Cancer, Radboud University Medical Center, Nijmegen, The Netherlands

Professor Hoogerbrugge, is a full professor in hereditary cancer at Radboud University Medical Center. Her ambition is to improve detection, diagnosis and treatment of hereditary cancer and prevent cancer in relatives specifically in PHTS. Her team detected that rare mutations in the NTHL1 gene, previously associated with colorectal cancer, also can cause breast cancer. She is the coordinator of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) (

Invited Speaker, Symposium

Karen Hurley, PhD
Clinical Psychologist - Hereditary Cancer Risk, Cleveland Clinic, Cleveland, OH, USA

Dr. Hurley, a licensed clinical psychologist at the Cleveland Clinic, has specialized for twenty years in hereditary cancer risk. After completing her A.B. at Bryn Mawr College, Ph.D. at Temple University, and postdoctoral fellowship at the Mount Sinai School of Medicine, she conducted NCI-funded research funded on surgical decision-making at Memorial Sloan-Kettering. She continued in private practice in Manhattan and taught graduate psychology at TC-Columbia University. She frequently presents for national/international audiences and is on the national advisory boards for FORCE, Bright Pink, Sharsheret, and the Cancer Support Community. In 2014, Dr. Hurley received FORCE’s Spirit of Empowerment Award for Individual Commitment.

Invited Speaker, Symposium, Public Conference

Paul James, MD, PhD
Director, Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Associate Professor James is a Clinical Geneticist from Melbourne. He is the director of the Parkville Familial Cancer Centre (Royal Melbourne Hospital and Peter MacCallum Cancer Centre) and Head of Clinical Genetics in the Department of Genomic Medicine (RMH). He is the group leader in Familial Cancer research at Peter MacCallum and leads a program of research involving familial disorders, supported by the Victoria Cancer Agency, Cancer Australia, Cancer Council NSW, the National Heart Foundation and the NHMRC.

Invited Speaker, Symposium

Yann Joly, PhD, Ad.E.
Research Director, Associate Professor, Centre of Genomics and Policy, McGill University, Montréal, QC, Canada

Yann Joly is the Research Director of the Centre of Genomics and Policy (CGP). He is an Associate Professor at the Faculty of Medicine, Department of Human Genetics cross-appointed at the Bioethics Unit, at McGill University. He was named advocatus emeritus by the Quebec Bar in 2012 and Fellow of the Canadian Academy of Health Sciences in 2017. His research interests lie at the interface of the fields of scientific knowledge, health law (biotechnology and other emerging health technologies) and bioethics. He has published his findings in over 120 peer-reviewed articles featured in top legal, ethical and scientific journals.

Invited Speaker, Symposium

Raymond Kim, MD, PhD, FRCPC, FACMG
Medical Geneticist, Princess Margaret Cancer Centre, Toronto, ON, Canada

Raymond Kim is a Medical Geneticist at the University of Toronto. He is Medical Director of the Familial Cancer Clinic at Princess Margaret Cancer Centre which identifies and follows all hereditary cancer syndromes. His interests include genomics in hereditary cancer patients and cell free DNA.

Proffered Paper, Symposium

Ephrat Levy-Lahad, MD
Director, Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel

Dr. Levy-Lahad is a Professor of Internal Medicine and Medical Genetics at Hebrew University and Director of the Medical Genetics Institute at Shaare Zedek Medical Center in Jerusalem. Since 1996, she has been Director of the Medical Genetics Institute and senior physician in the Department of Medicine at Shaare Zedek Medical Center. She holds a faculty appointment as Professor in Medicine and Genetics at the Hebrew University-Hadassah Medical School in Jerusalem. Her clinical laboratory includes cancer genetics diagnostics and a large pre-implantation diagnosis service. Her research laboratory focuses on population genetics of breast and ovarian cancer, in particular the BRCA1 and BRCA2 genes. She is active in bioethical aspects of genetic research, and is currently co-Chair of the Israel National Bioethics Council. She is a member of Israel's National Council for Women's Health and the National Council for Gyncology, Perinatal Medicine and Genetics. Internationally, she was a member of UNESCO's IBC (International Bioethics Committee) (2006-2009).

Invited Speaker, Symposium

Zoe Lohn, MSc, CCGC, CGC
Genetic Counsellor, BC Cancer, Vancouver, BC, Canada

Zoe Lohn is a clinical genetic counsellor with the BC Cancer Hereditary Cancer Program. She is a lecturer and clinical supervisor for the genetic counselling students at the University of British Columbia. Ms Lohn lives in Vancouver, BC.

Proffered Paper, Symposium

Justin Lorentz, CGC
Genetic Counsellor, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

Justin Lorentz graduated from McGill’s genetic counselling program and is a certified genetic counsellor. He practices clinically at Medcan and he is the lead of the Sunnybrook Odette Cancer Centre's Male Oncology Research and Education (MORE) Program; a registry for men with hereditary cancer. He is affiliated with the University of Toronto as a lecturer. His current academic interests are in hereditary cancer with a focus on male breast cancer and prostate cancer.

Invited Speaker, Symposium, Public Conference

Lisa Madlensky, PhD, CGC
Director, Family Cancer Genetics Program, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

Dr. Madlensky has provided cancer genetic counseling services for over 20 years. She has practiced in the United States and Canada, and was a founding member of the Familial Cancer Risk group of the National Society of Genetic Counselors (NSGC), establishing cancer genetic counseling as a sub-specialty. Clinical research themes include clinical genetic testing and follow-up for families with familial cancer risk, the public health implications of cancer genetic testing, quality of life in those at increased risk of cancer, the integration of cancer risk assessment into family practice, and family-level cancer prevention. Dr. Madlensky also studies the impact of direct-to-consumer genetic testing and the relationship between germline and somatic mutations in cancer.

Invited Speaker, Symposium

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

Dr. Matulonis is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer.

Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and internationally. She serves on the Massachusetts Ovarian Cancer Task Force, the NRG ovarian committee,and the Scientific Advisory Board for the Ovarian Cancer Research Alliance, the Rivkin Foundation, the Clearity Foundation, and Overcome. She has received the Dana-Farber Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Clearity Foundation award, the Zakim Award at Dana-Farber for patient advocacy, and recently in 2020, the Albany Medical College Alumni Association DistinguishedAlumna Award.

After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.

Invited Speaker, Symposium

Colin McIlmunn, MB BCh
Clinical Academic Research Fellow, Queen's University Belfast, Belfast, Northern Ireland

Colin McIlmunn graduated from Queen’s University, Belfast in 2008 with a degree in medicine. He was awarded a national training number in General Surgery in 2013. Following a clinical research fellowship at Queen’s University, he successfully defended his PhD thesis in February 2021. Currently, he is a senior surgical registrar with a sub-specialist interest in Oncoplastic Breast Surgery, living in Northern Ireland with his wife and three daughters.

Proffered Paper, Symposium

Wendy McKinnon, MS, CGC
Genetic Counselor, University of Vermont Cancer Center, Burlington, VT, United States

Wendy McKinnon is a certified genetic counselor who specializes in genetic counseling and testing for familial cancer. She is the coordinator for the Familial Cancer Program at the University of Vermont Cancer Center, where she has worked since graduating from the University of Michigan’s genetic counseling program. She has been in the field of cancer genetic counseling since its inception and has been involved in publishing guidelines for practice, as well as involved in a number of research studies related to the field.

Invited Speaker, Symposium

Steven Narod, MD, FRCPC, FRSC
Senior Scientist, Women's College Research Institute, Toronto, ON, Canada

Dr. Narod is a world-leader in the field of breast and ovarian cancer. He has shaped current knowledge of how to assess breast and ovarian cancer risk and reduce its mortality among carriers of BRCA1 and BRCA2 mutations. He studies various aspects of cancer prevention and screening. He is a Tier I Canada Research Chair in Breast Cancer, a University of Toronto professor in the Dalla Lana School of Public Health and the Department of Medicine, and a senior scientist at Women’s College Research Institute, where he leads the Familial Breast Cancer Research Unit.

In 2012, Dr. Narod was elected a Fellow of the Royal Society of Canada. He holds two honorary degrees. He received the 2016 Killam Prize in health sciences and the 2015 Basser Global Prize. With more than 900 peer-reviewed publications and an h-index of 114, Dr. Narod is one of the most cited cancer researchers in the world.

Invited Speaker, Symposium

Sarah Nielsen, MS, LCGC
Genetic Counselor, Medical Affairs Liaison, Invitae, San Francisco, CA, United States

Sarah Nielsen, MS, LCGC is a genetic counselor and clinical program manager for oncology at Invitae. She was previously a genetic counselor, clinical researcher and Assistant Director of the University of Chicago Center for Clinical Cancer Genetics. She was also a co-director of both the University of Chicago High-Risk and Advanced Prostate Cancer Clinic and the von Hippel-Lindau (VHL) Comprehensive Clinical Care Center. Her research and professional interests are focused on the genetics of prostate cancer, genetic & environmental modifiers of risk in diverse populations, and expanding access to genetics services to underrepresented and underserved populations.

Proffered Paper, Symposium

Serena Nik-Zainal MD, PhD
CRUK Advanced Clinician Scientist, University of Cambridge, Cambridge, United Kingdom

Dr. Nik-Zainal is a CRUK Advanced Clinician Scientist and Honorary Consultant in Clinical Genetics in Cambridge, UK. She went to the UK as a PETRONAS scholar from Malaysia in 1993, obtaining a First in Physiology at University of Cambridge before completing her medical degree in 2000. She trained as a physician and specialized in Clinical Genetics. She undertook a PhD at the Wellcome Sanger Institute in 2009 pioneering exploration of breast cancers through whole genome sequencing (WGS).

Dr. Nik-Zainal demonstrated how detailed downstream analyses of all mutations present in WGS breast cancers could reveal mutational signatures, imprints left by mutagenic processes that have occurred through cancer development. She also identified a novel phenomenon of localised hypermutation termed 'kataegis'. She continues to explore large cancer datasets using computational approaches while investigating biological underpinnings of mutational signatures through cell-based model systems. She led a clinical project, Insignia ( recruiting patients with DNA repair/replication defects, aging syndromes and neurodegeneration and is also focused on advancing the field into the clinical domain.

Invited Speaker, Symposium

Laura Palma, MSc, CGC, CCGC
Genetic Counsellor. Assistant Professor, Department of Medical Genetics, McGill University Health Centre (MUHC), Montréal, QC, Canada

Laura Palma received her Master’s degree in Genetic Counselling from the University of Toronto in 2005 and joined the Department of Medical Genetics at the McGill University Health Center (MUHC) shortly after graduation. In her present role as a clinical cancer genetic counsellor, she counsels patients and families at risk for a variety of hereditary cancer syndromes, both in the adult and pediatric settings. She is actively involved in course coordination, teaching, and clinical supervision of genetic counselling students and residents through the McGill Department of Human Genetics. She is also a sitting member on the MUHC clinical ethics committee. Her research interests are in the area of hereditary cancer and models of genetic service delivery.

Session Chair, Public Conference

Paul Pharoah, BM, BCh, PhD
Professor of Cancer Epidemiology, University of Cambridge, Cambridge, UK

Professor Pharoah qualified in medicine from the University of Oxford in 1986. After a series of posts in internal medicine he worked for a year in Malawi on a leprosy vaccine trial. He then completed his training in public health medicine before taking up a post as research fellow in the CRC Human Cancer Genetics group at the University of Cambridge in 1996. Having completed his doctoral studies in 1999 he won a Cancer Research UK Senior Clinical Research Fellowship in 2004 and his fellowship was renewed. On completion of his fellowship in 2009 he was appointed Reader in Cancer Epidemiology and promoted to a personal Chair in 2012, Department of Public Health and Primary Care, University of Cambridge.

His major research interests are i) common genetic variation and breast and ovarian cancer susceptibility and ii) the role of germline genotype in determining the clinical and molecular pathological characteristics of breast and ovarian cancer. Professpr Pharoah has published over 500 papers reporting original research as well as numerous book chapters and review articles.

Invited Speaker, Symposium

Paz Polak, PhD
Assistant Professor, Mount Sinai Hospital, New York, NY, United States

Dr. Polak, is an Assistant Professor in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai Hospital. His lab focus is on the etiology of breast cancer across different populations via multiple genomic and computational techniques. Currently, his lab studies the genomes of Caribbean and African American cancer patients in the US. He also intends to study cancer genomes of the different populations via international partnerships with cancer researchers from Brazil, Ghana, and the Dominican Republic.

Proffered Paper, Symposium

Mark Robson, MD
Chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Dr. Robson graduated from the University of Virginia School of Medicine in Charlottesville, Virginia, and did his internal medicine residency and hematology-oncology fellowship training at Walter Reed Army Medical Center in Washington DC. He is currently Chief of the Breast Medicine Service in the Department of Medicine at Memorial Hospital in New York, an attending physician on Breast Medicine and Clinical Genetics Services, and a Member of the Memorial Sloan Kettering Cancer Center. His clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation – associated breast cancer. In addition to developing PARP inhibition as a therapeutic strategy, he is currently developing new models for the acquisition of germline information, including "mainstreaming" through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He is currently investigating the use of polygenic risk scores in facilitating decision-making among women with or without an inherited predisposition. He serves on the editorial board of the Journal of Clinical Oncology and is an associate editor for the Journal of the National Cancer Institute. He is past chair of the Ethics Committee of the American Society of Clinical Oncology and has served several terms on the ASCO Cancer Prevention Committee and its Cancer Genetics subcommittee.

Invited Speaker, Symposium

Matti Rookus, PhD
Senior Researcher. Netherlands Cancer Institute, Amsterdam, The Netherlands

Dr. Rookus’ main field of interest as an epidemiologist is the etiology of breast and ovarian cancer, with focus on modifiable lifestyle risk factors such as use of oral contraceptives and hormone replacement therapy, physical activity, Body Mass Index, early lifestyle factors and chronodisruption. She conducts national prospective cohort studies on shift work (Nightingale study), in utero exposure to Diethylstilbestrol (DESnet study), on familial breast and ovarian cancer (HEBON Study) and she coordinates the prospective International BRCA1/2 mutation Carrier Cohort Study (IBCCS).

Proffered Paper, Symposium

Marjanka Schmidt, PhD
Group Leader and Professor of genetic epidemiology of (breast) cancer, Netherlands Cancer Institute, Amsterdam, and Leiden University Medical Center, Leiden, The Netherlands

Professor dr. Schmidt is a group leader at the Division of Molecular Pathology at the Netherlands Cancer Institute and a professor of genetic epidemiology of (breast) cancer at Leiden University Medical Center, the Netherlands. The research of her group focusses on germline and somatic variants related to breast cancer risk and outcome, including long-term survival and second tumors; and on practical ethical, legal and social implications (ELSI) of use of patient data and materials. She has been involved in the set-up and curation of national and international breast cancer cohorts and published over 200 peer-reviewed papers. She co-leads the pathology and survival working group of the Breast Cancer Association Consortium and is the coordinator of B-CAST, an EU grant focusing on stratification of breast cancer risk and prognosis.

Invited Speaker, Symposium

Ralph Scully, MBBS, PhD
Professor of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States

Dr. Scully majored in Medical Sciences and English at the University of Cambridge UK and completed his medical training at University College London in 1986. Following several years of medical practice, he undertook training in basic research and was awarded a Ph.D. on mechanisms of immunological tolerance by the University of Cambridge in 1994. He moved to Harvard Medical School for postdoctoral training with David Livingston at the Dana Farber Cancer Institute. There, he uncovered roles for the major hereditary breast and ovarian cancer predisposition genes, BRCA1 and BRCA2, in double strand break repair and homologous recombination. His lab studies the mechanisms of action of BRCA1 and BRCA2 in DNA repair to better understand their roles as tumor suppressors and as a path to the discovery of new cancer therapies.

Invited Speaker, Symposium

Shyam Sharan, PhD
Deputy Program Director, Mouse Cancer Genetics Program, National Cancer Institute, NIH Frederick, MD, USA

Dr. Sharan obtained his Ph.D. in Genetics from Case Western Reserve University, Cleveland, OH and was a postdoctoral fellow at Baylor College of Medicine, Houston, TX. Since 1998, his laboratory at NCI has used mouse ES cells and genetically engineered mouse models for functional analysis of BRCA1 and BRCA2.

Proffered Paper, Symposium

Valentina Silvestri, MSc., PhD
Research Fellow, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

Dr. Silvestri is a post-doctorate research fellow at Sapienza University of Rome. After graduating in Genetics and Molecular Biology in 2009, she attended advanced postgraduate courses in biostatistics and bioinformatics. Her research focus is the characterization of genetic susceptibility, molecular basis and pathology of male breast cancer.

Proffered Paper, Symposium

Jacques Simard, PhD, FACSS, ACS
Chairholder of the Canada Research Chair in Oncogenetics, Vice-Dean of Research and Graduate Studies, Full Professor, Department of Molecular Medicine, Faculty of Medicine, Université Laval
CHU de Québec – Université Laval Research Center, Québec, QC, Canada

Since the early 90s, Professor Simard’s work has focused on deciphering the contribution of genetic factors in the susceptibility of hormone-sensitive cancers. He heads, since 2001, a large interdisciplinary and international research teams on genetic susceptibility to breast cancer bringing together molecular geneticists, epidemiologists, biostatisticians, clinicians, and ethicists from North America and Europe.

He led a large-scale project entitled Personalized Risk Stratification for Prevention and Early Detection of Breast Cancer (PERSPECTIVE, 2013-2018), designed to develop the tools needed to implement a risk stratification approach that would target breast cancer screening in women most likely to develop the disease. Currently, he leads the Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I) project designed to generate real-world evidence on acceptability, uptake and cost-effectiveness as well as addressing socio-ethical and legal issues of a risk-based screening approach in the Canadian public health care system.

Proffered Paper, Symposium

Jana Soukupová, PhD
Assistant Professor, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic

Dr. Soukupova graduated (MSc) from molecular biology at Masaryk University in Brno. Since her PhD studies at Medical Faculty, Charles University in Prague, her research activities have focused on hereditary ovarian cancer genetics. She holds certification in clinical genetic diagnostics.

Proffered Paper, Symposium

Lea Starita, PhD
Assistant Research Professor, University of Washington, Seattle, WA, United States

Dr. Starita is an Assistant Research Professor in the Genome Sciences department at the University of Washington and co-director of the Advanced Technology Lab at the Brotman Baty Institute for Precision Medicine where she develops massively parallel methods to determine the effects of genetic variation on protein function. Using this approach, she hopes to help solve the problem of variants of uncertain significance by scoring the pathogenic potential of genetic variants before they are found in the clinic.

Invited Speaker, Symposium

Miranda Steenbeek, MD,
PhD Student, Radboud University Medical Center, Nijmegen, The Netherlands

Dr. Steenbeek graduated as a medical doctor from the Radboud university (The Netherlands) in 2015 and started as a gynecologist in training. In 2017 she started her PhD on ovarian cancer prevention in BRCA mutation carriers under supervision of Joanne de Hullu, gynecologic oncologist and principal investigator of the TUBA study.

Proffered Paper, Symposium

Kári Stefánsson, MD, PhD
deCODE Genetics, Reykjavík, Iceland

Dr. Stefánsson is founder and CEO of Reykjavik-based deCODE genetics. In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome. His work, published in more than 600 scientific papers, has focused on how genomic diversity is generated and on the discovery of sequence variants impacting susceptibility to common diseases. The population approach he has advanced in Iceland has served as the model for national genome projects around the world and contributed to the realization of several aspects of precision medicine, including to the discovery and development of therapeutic targets and compounds for Amgen. Prior to founding deCODE in 1996 he was professor of neurology, neuropathology and neuroscience at Harvard and had previously held faculty positions in neurology, neuropathology and neurosciences at the University of Chicago, from 1983-1993.

Dr. Stefánsson has received some of the highest honors in biomedical research and genetics, including the Sackler Lecture at MIT, the European Society of Human Genetics Award, the Anders Jahre Award, the American Alzheimer’s Association’s Inge Grundke-Iqbal Award, the Federation of European Biomedical Societies’ Sir Hans Krebs Medal, and the American Society of Human Genetics (ASHG) William Allan Award. His work has been recognized by major international publications and bodies including Time, Newsweek, Forbes, BusinessWeek and the World Economic Forum. He holds Iceland's highest honor, the Order of the Falcon, and in 2019 was elected the first president of the Nordic Society of Human Genetics and Precision Medicine.

Invited Speaker, Symposium

Kelly Tangney, MS, LCGC
Head of Clinical Services, Color Health, Inc., Valencia, CA, United States

Kelly Tangney, is the Head of Clinical Services at Color and lead genetic counselor for the All of Us Research Program Genetic Counseling Resource. She joined Color in 2015 with a focus on counseling patients and their families at risk for hereditary adult-onset conditions and expanding Color's mission of broadening access to genetic testing. She now manages a team of remote clinical genetic counselors across the country that carry out genetic counseling services for clients that undergo Color clinical genetic testing and remotely supervises genetic counseling students. Since earning her B.S. in Psychobiology from the University of California, Los Angeles (UCLA) and her M.S. in Genetic Counseling from California State University, Stanislaus but prior to joining Color, she worked at UCLA, Kaiser Permanente and the Veterans Administration Los Angeles as a general adult genetic counselor.

Invited Speaker, Symposium

Marc Tischkowitz, MD, PhD
Associate Professor, University of Cambridge, Cambridge, UK

Dr. Tischkowitz is a Reader in Medical Genetics at the University of Cambridge and an Honorary Consultant Physician in the East Anglian Medical Genetics Service. He completed his medical degree in 1993 and trained Medical Oncology before completing his specialisation in Medical Genetics. From 1999-2002 he undertook a PhD researching the role of Fanconi anemia gene mutations in the development of sporadic acute myeloid leukaemia. He held a Consultant post at Great Ormond Street Hospital before moving to McGill University, Montreal in 2005 where he worked on Faculty for six years before coming to Cambridge. Much of his research has been on the Fanconi Anemia genes and hereditary breast cancer predisposition but his interests cover all areas of hereditary cancer and at present he is focused on translating the recent advances in genomic technology into clinical practice..

Invited Speaker, Symposium

Patricia Tonin, PhD
Professor and Senior Scientist, The Research Institute of the McGill University Health Centre, Montréal, QC, Canada

Dr. Tonin earned her doctoral degree at the University of Toronto, and completed postdoctoral studies at the Montreal General Hospital Research Institute where she participated in the discoveries of BRCA1 and BRCA2. Her research activities include the study of the contribution of hereditary factors in breast and ovarian cancer families, and somatic genetic events associated with the development of ovarian cancer in the French Canadian population of Québec.

Session Chair, Symposium

Alison Trainer, FRACP, PhD
Clinical Geneticist, Peter MacCallum Cancer Center, Melbourne, Australia

Dr. Trainer is a Clinical Geneticist based in the Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre Melbourne. She completed her training in clinical genetics in the UK before obtaining a PhD in metabolic transgenic mouse models at Glasgow University. She spent 3 years as a doctoral scientist in the laboratory of Prof. A. Venkitaraman, MRC Cell Cancer Unit, University of Cambridge, exploring the role of BRCA2 in chromosome segregation. Dr. Trainer has research interests in health services, economic modelling and male breast cancer.

Proffered Paper, Symposium

Laufey Tryggvadóttir, MSc.
Professor, Managing Director, University of Iceland / Icelandic Cancer Registry, Reykjavik, Iceland

Professor Tryggvadóttir is a specialist in biology and epidemiology, professor at the Faculty of Medicine, University of Iceland and managing director of the Icelandic Cancer Registry. She is also a member of the steering committee for Nordic Summer School in Cancer Epidemiology and the board of directors for Association of Nordic Cancer Registries since 1989. She is the author of 284 peer reviewed publications.

Proffered Paper, Symposium

Clare Turnbull, MD, PhD, MFPH
Professor of Translational Cancer Genetics, Institute of Cancer Research, London, United Kingdom

Professor Turnbull is a UK clinician-researcher in the field of cancer susceptibility genomics based at the Institute of Cancer Research, London and Genomics England Ltd. She has published extensively in genetic susceptibility to breast, ovarian, testicular and childhood cancers, including early GWAS in breast cancer and identification of RAD51D and RAD51C as susceptibility genes for ovarian cancer.

Invited Speaker, Symposium

Evan Weber, MSc, CGC, CCGC
Genetic Counsellor, Medical Genetics, McGill University Health Centre (MUHC), Montréal, QC, Canada

Evan Weber is a genetic counsellor at the McGill University Health Centre in Montreal, specializing in hereditary cancer. He is a Faculty Lecturer in the Department of Human Genetics at McGill University, and is actively involved in the training of genetic counselling students. He is certified by the Canadian Association of Genetic Counsellors and the American Board of Genetic Counselors. He is a graduate of the University of Toronto MSc in Genetic Counselling Program. His clinical and research interests include genetic testing for ovarian cancer, and pediatric hereditary cancer syndromes.

Session Chair, Public Conference

Britta Weigelt, PhD
Director, Gynecology Research Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Dr. Weigelt received her PhD from the Netherlands Cancer Institute/ University of Amsterdam, The Netherlands, and undertook her postdoctoral training at Lawrence Berkeley National Laboratory, Berkeley, USA, and Cancer Research UK London Research Institute, London, UK, before moving to Memorial Sloan Kettering Cancer Center in New York, USA in 2012.

She is a Molecular Geneticist and the Director of the Gynecologic Research Laboratory at Memorial Sloan Kettering Cancer Center. Her research interests include the identification of biologically relevant subclasses of breast and gynecologic cancers and their driving molecular alterations through high-throughput genomics and functional genomics, the determination of strategies to overcome the challenges posed by intra-tumor genetic heterogeneity through cfDNA and single cell sequencing analyses, and the study of the somatic genetics of hereditary breast and gynecologic cancers. She serves on the Editorial Board of the Journal of the National Cancer Institute, the Journal of Pathology and the European Journal of Cancer.

Invited Speaker, Symposium

Jeffrey Weitzel, MD
Latin American School of Oncology, Sierra Madre, CA, USA

Dr. Weitzel was board Certified in Medical Oncology and Clinical Genetics, and founded the Clinical Cancer Genomics Community Research Network. A Breast Cancer Research Foundation Scholar and an honorary Professor of Oncology for the Latin American School of Oncology, he is also the ASCO Conquer Cancer Research Professor in Breast Cancer Disparities. At the vanguard of precision prevention, Dr. Weitzel’s multidisciplinary clinical, research, and training experience emphasize translational research in cancer disparities, genomic cancer risk assessment, chemoprevention, targeted therapy, clinical and psychosocial outcomes, genetic epidemiology and health services research, with a focus on underserved populations. Dr. Weitzel received the American Society of Human Genetics Arno Motulsky-Barton Childs Award for Excellence in Human Genetics Education.

Invited Speaker, Symposium

George Zogopoulos, MD, PhD
McGill University Health Centre, Montréal, QC, Canada

Dr. Zogopoulos completed his clinical training at the University of Toronto, and his research training at McGill University and at the University of Toronto. He obtained his PhD in Experimental Medicine at McGill University, where he studied the regulatory mechanisms of a gene responsible for human growth. He pursued postdoctoral research training during his residency, enrolling in the surgeon-scientist program of the University of Toronto. His research fellowship was undertaken at the Samuel Lunenfeld Research Institute, where he studied the hereditary aspects of colon and pancreas cancer. His current research focuses on gastrointestinal cancer genetics, with an emphasis on pancreas cancer.

Invited Speaker, Symposium